Compare CDMOs manufacturing sterile injectable products for IV, subcutaneous, and intramuscular administration. Filter by container type, aseptic technology, and capacity.
326 companies listed
Sterile injectable manufacturing produces parenteral products administered by injection. These products bypass the body's natural defense barriers, making sterility the paramount quality attribute. Manufacturing must occur in classified cleanroom environments with validated aseptic processes.
The sterile injectable market is growing faster than overall pharma, driven by biologics (monoclonal antibodies, ADCs, vaccines), complex generics (liposomal formulations, microspheres), and the shift toward self-administered subcutaneous products. CDMOs with modern isolator-based filling lines, lyophilization capability, and multiple container format experience are the most competitive.
Japan
JCR Pharmaceuticals is a Japanese pharmaceutical company and CDMO founded in 1975, with nearly 50 years of experience in rare disease treatments and orphan drug production. Selected for Japan's Regenerative Medicine CDMO Subsidy Program in 2025, the company is expanding biomanufacturing infrastructure for cell, gene, and regenerative medicine therapies. JCR operates five production sites and has proprietary platforms including JUST-AAV for gene therapy and J-Brain Cargo for blood-brain barrier penetration.
United States
Jerome Stevens Pharmaceuticals, Inc. (JSP) is a family-owned pharmaceutical manufacturer based in Bohemia, New York, established in 1979. The company specializes in manufacturing prescription tablet and capsule formulations under cGMP standards. JSP is notable for manufacturing UNITHROID, the first FDA-approved Levothyroxine Sodium product, and also produces Digoxin tablets. The company provides CMO services to partners including Amneal Pharmaceuticals.
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.